NuVue Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.
You may also be interested in...
Start-Up Previews (12/2010)
A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.